[PEGS 2023] Accelerate Drug Development of GLP-1 & -2 Receptor Analogs with Ready-to-Use Cell-Based Assays
- File Name/Number:
- PEGS
- Year:
- 2023
There is an increasing need to generate therapeutics targeting metabolic and gastrointestinal diseases to address the global burden of metabolic diseases. By targeting G protein-coupled receptor (GPCRs) such as glucagon-like peptide (GLP-1 and GLP-2) receptors, therapeutics can be developed to address these globally prevalent medical disorders. In particular, engineered recombinant agonist analogs targeting the GLP-1 receptor are FDA approved for managing type-2 diabetes and body weight disorders, while GLP-2 analogs have been under therapeutic focus for the treatment of short bowel syndrome, a serious unmet medical disorder. Several other novel GLP analogs, including biosimilars are in clinical development; however, existing assays for characterizing their mechanism of action (MOAs) are complex and require extensive development time.